Discover

Back to filter

Related topics

Cytek full Spectrum flow Cytometry webinar: Part II – panel design and troubleshooting

Cytek Biosciences

Jan 11, 2021

In this session, we will continue to look at full spectrum flow cytometry and look at considerations for fluorescence...

IncuCyte for in-vitro analysis of SARS-CoV-2 vaccine candidate

Sartorius

Jan 4, 2021

Watch this video to learn how researcher at Humane Genomics are utilizing the Incucyte platform for the in-vitro...

Cesium-137 versus X-ray irradiation preconditioning in immunodeficient NOG mice

Precision X-Ray

Dec 29, 2020

Radio-active sources have been used routinely for the preconditioning in humanized mouse models, but safety issues have...

Coming in spring 2021, meet the Cytek Aurora CS

Cytek Biosciences

Dec 18, 2020

Ever wanted to take your full spectrum panel from your Cytek Aurora or Northern Lights cytometer and sort? Soon, you...

Advances in Leukemia research using shear flow and Bioflux system

Fluxion Biosciences

Dec 10, 2020

Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...

Do you have our CellRad benchtop irradiator? It’s the only one on the market!

Precision X-Ray

Dec 9, 2020

The CellRad is a smaller, simpler, safer, and more cost effective alternative to radioisotope or high-powered X-ray...

Dosimetric characterization of an X-ray irradiator for use with cells

Precision X-Ray

Dec 4, 2020

This study aims to characterize an X-ray irradiator for use with cells using its internal parallel-plate ionization...

Curiox - how to retain more cells for Single Cell Sequencing and proteogenomics ?

Curiox

Nov 19, 2020

Do you think that centrifuging cells at 500 x g is not going to cause issues? Moreover, sample prep involving...

CS-FNX Hitachi Koki, discover the state-of-art ultracentrifuges series

Hitachi Koki

Nov 19, 2020

Hitachi Koki, as a world leading producer of centrifuges offers general purpose floor standing and table top...

Discover the new NovoCyte Penteon - when exceptional performance meets simplicity

Agilent technologies

Nov 18, 2020

The NovoCyte Penteon flow cytometer builds on its successful predecessor, the NovoCyte. You now have the flexibility to...

Show all topics (10)

Preclinical cardiac safety assesment

Mar 22, 2016

Over the last two decades, a number of blockbuster drugs have been withdrawn or have incurred safety warnings by regulatory agencies due to adverse cardiac effects. In addition, lead compounds or drug candidates are frequently terminated at late stages of drug development due to cardiac safety concerns. Both of these factors can significantly impact the overall cost of drug discovery; consequently, pharmaceutical companies and regulatory agencies have implemented procedures to address these issues.

Most, if not all, in vitro assay systems for cardiac safety are designed to screen for surrogates of arrhythmia, such as hERG channel interaction, rather than arrhythmia itself. Assays designed to screen for compounds that may affect repolarization and induce arrhythmia in the context of the whole heart or heart tissue are not implemented until much later in drug development. These include sophisticated, technically demanding, lowthroughput, and costly procedures such as the Purkinje fiber assay, ventricular wedge assay, and the Langendorff whole heart assay, or telemetry experiments in live and anesthetized animals. The field of preclinical cardiac safety can certainly benefit from an assay system that allows for integrated assessment of compound action on ion channel and non-ion channel targets involved in cardiac excitation-contraction coupling.

The RTCA Cardio Instrument in conjunction with iCell Cardiomyocytes comprises an assay system providing integrated assessment of compound action on multiple targets involved in heart function. This assay system can sensitively and quantitatively detect the effect of compounds on the major ion channels involved in heart function, namely calcium, sodium, and potassium channels. Another major advantage of the assay system is the time resolution. The RTCA Cardio Instrument has a data acquisition rate of 12.5 ms per well of a 96-well plate and can be used simultaneously to monitor acute and chronic drug effects up to days and weeks. The utility of the time-dependent monitoring of compound action on cardiomyocytes can be demonstrated by testing compounds that acutely and directly block hERG channels (E4031, cisapride, etc.) and compounds that interfere with protein trafficking (pentamidine) in a sub-chronic manner. The RTCA Cardio Instrument is able to detect the effects of these compounds on the beating rate and duration of iCell Cardiomyocytes.

The xCELLigence System RTCA Cardio Instrument, in conjunction with iCell Cardiomyocytes, represents a physiologically relevant and predictive assay system for preclinical cardio-safety assessment of lead compounds. The features of this assay system, including time resolution, dynamic monitoring of mechanical beating activity of cardiomyocytes, and 96-well throughput, will surely provide additional mechanistic and toxicity information for compound action on the heart.

Application
Product news

Brand profile

Agilent technologies

Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

Cardio Instrument is a high-resolution system for label-free-dual-mode monitoring of cardiomyocyte and cardiotoxicity testing

show detail

The new CardioECR system combines impedance and Multi Electrode Array (MEA) technology with a pacing function

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey